Stock ALTIMMUNE INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Altimmune Inc Nasdaq

Equities

US02155H1014

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT
PR
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
PR
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
NE
Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
AQ
Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association?s 84th Scientific Sessions
CI
Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions
AQ
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
PR
Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT
PR
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
PR
Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways
AQ
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights - ALT
PR
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association's Scientific Sessions
AQ
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
PR
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions
AQ
ALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
PR
Health Care Flat as Traders Wait More Obesity-Drug Updates - Health Care Roundup
DJ
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT
PR
TOP RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
NE
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
PR
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune Lawsuit - ALT
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALT Stock
  4. Stock
  5. News Altimmune Inc